Aralez Pharmaceuticals (TSE:ARZ) Lowered to Accumulate at Bloom Burton

Bloom Burton cut shares of Aralez Pharmaceuticals (TSE:ARZ) from a buy rating to an accumulate rating in a report published on Wednesday, March 14th.

Separately, HC Wainwright restated a buy rating on shares of Aralez Pharmaceuticals in a report on Monday, February 5th.

How to Become a New Pot Stock Millionaire

Shares of ARZ traded down C$0.05 on Wednesday, hitting C$1.80. 11,920 shares of the stock traded hands, compared to its average volume of 25,193. Aralez Pharmaceuticals has a one year low of C$1.20 and a one year high of C$3.72.

Aralez Pharmaceuticals (TSE:ARZ) last announced its quarterly earnings results on Tuesday, March 13th. The company reported C($0.48) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of C($0.43) by C($0.05). The firm had revenue of C$35.59 million for the quarter, compared to the consensus estimate of C$32.38 million. Aralez Pharmaceuticals had a negative net margin of 100.42% and a negative return on equity of 146.16%.

WARNING: This story was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/04/07/aralez-pharmaceuticals-arz-stock-rating-lowered-by-bloom-burton.html.

About Aralez Pharmaceuticals

Aralez Pharmaceuticals Inc operates as a specialty pharmaceutical company in the United States and Canada. It engages in acquiring, developing, and commercializing products primarily in cardiovascular disease, pain, and other specialty areas. It offers Yosprala for patients who require aspirin for secondary prevention of cardiovascular and cerebrovascular events; Toprol-XL, a cardioselective beta-blocker indicated for the treatment of hypertension; Fibricor, a fenofibric acid for the treatment of severe hypertriglyceridemia; Zontivity for the reduction of thrombotic cardiovascular events in patients; Cambia, a non-steroidal anti-inflammatory drug (NSAID) for the acute treatment of migraine attacks; Fiorinal and Fiorinal C for the relief of tension type headaches; and Soriatane for the treatment of severe psoriasis and other disorders of keratinization.

Receive News & Ratings for Aralez Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply